Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.